International Journal of Gynecological Cancer最新文献

{"title":"Pelvic peritonectomy versus rectosigmoid resection in advanced epithelial ovarian cancer with Douglas pouch involvement: a systematic review and meta-analysis.","authors":"Martina Aida Angeles, David Viveros-Carreño, Giulio Bonaldo, Vicente Bebia, Núria Agustí, Ana Luzarraga Aznar, Úrsula Acosta, Naia Seminario, René Pareja, Antonio Gil-Moreno","doi":"10.1016/j.ijgc.2025.101983","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101983","url":null,"abstract":"<p><strong>Objective: </strong>To compare the oncologic outcomes in patients with advanced epithelial ovarian cancer and Douglas pouch involvement who underwent pelvic peritonectomy vs rectosigmoid resection as part of cytoreductive surgery.</p><p><strong>Methods: </strong>A systematic literature review and meta-analysis were conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses checklist. MEDLINE (through Ovid), Embase, and Cochrane Central Register of Controlled Trials were searched from inception until March 2024. We included studies with 2 arms of intervention comparing pelvic peritonectomy and rectosigmoid resection in patients diagnosed with advanced epithelial ovarian cancer (International Federation of Gynecology and Obstetrics 2014 stage IIB-IVB). Randomized controlled trials and prospective and retrospective observational studies were considered. The protocol was registered in PROSPERO (CRD42024535681).</p><p><strong>Results: </strong>The search identified 821 articles; 598 studies were considered potentially eligible after removing duplicates, and 4 met the selection criteria, including a total of 623 patients. All 4 studies were retrospective. There was no statistically significant difference between patients undergoing pelvic peritonectomy compared to rectosigmoid resection in terms of overall recurrences (OR 0.99, 95% CI 0.53 to 1.83, I² = 60%, p = .97; 3 studies, 495 participants) or pelvic recurrences (OR 1.61, 95% CI 0.23 to 11.53, I² = 88%, p = .63; 3 studies, 495 participants). Similarly, there were no significant differences in 5-year disease-free survival (OR 0.91, 95% CI 0.13 to 6.43, I² = 91%, p = .93; 2 studies, 317 participants), or 5-year overall survival (OR 1.02, 95% CI 0.39 to 2.62, I² = 83%, p = .97; 4 studies, 623 participants). Operative time, stoma rate, blood loss, blood transfusion, and length of hospital stay were significantly higher in the rectosigmoid resection group in the studies where these outcomes were assessed.</p><p><strong>Conclusions: </strong>The comparison between pelvic peritonectomy and rectosigmoid resection for the treatment of Douglas pouch carcinomatosis in advanced ovarian cancer revealed no significant differences in overall and pelvic recurrence rates. Disease-free and overall survival were comparable between the 2 surgical techniques. However, pelvic peritonectomy was associated with shorter surgeries, reduced stoma formation, shorter hospital stay, and lower blood loss and transfusion requirements.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101983"},"PeriodicalIF":4.1,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144617377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative immunonutrition for patients who undergo primary cytoreductive surgery for ovarian cancer.","authors":"Ryan Kahn, Evan Smith, Kimberly Murphy, Effi Yeoshoua, Lianne Russo, Qin Zhou, Alexia Iasonos, Gabrielle Bennetti, Bhavani Ramesh, Nadeem R Abu-Rustum, Dennis S Chi, Oliver Zivanovic, Ginger Gardner, Kara Long Roche, Yukio Sonoda, Eric Schroeder, John Diaz, Vance Broach","doi":"10.1016/j.ijgc.2025.101980","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101980","url":null,"abstract":"<p><strong>Objective: </strong>The role of preoperative immunonutrition interventions in patients with gynecologic malignancies has not been well studied.</p><p><strong>Methods: </strong>We performed a prospective observational study to assess the feasibility of a preoperative immunonutrition supplementation plan in patients with advanced ovarian cancer who underwent primary cytoreductive surgery between August 2019 and November 2022. Patients were encouraged to consume the provided immunonutrition supplement at each meal for up to 7 days prior to surgery. Patients completed standardized daily intake surveys, as well as laboratory tests and weight measurements throughout the study.</p><p><strong>Results: </strong>A total of 29 patients were enrolled, 17 of whom met the inclusion criteria. Participants demonstrated a median weight gain of 3.8 kg over the study period, with high compliance, consuming an average of 2.2 Ensure Surgery Immunonutrition Shakes per day. On the day of surgery, 16 of 17 patients (94%) found the supplement satisfying, and 12 (71%) reported feeling better prepared for surgery. The median postoperative hospital stay was 8 days (interquartile range; 6-9), and the median time from surgery to initiation of chemotherapy was 36 days (interquartile range; 35-40). Preoperative laboratory assessments showed significant increases in neutrophils (+4.27 cells/μL, p < .001), C-reactive protein (+23.03 mg/L, p < .001), interleukin-6 (+160.22 pg/mL, p < .001), and interleukin-10 (+4.62 pg/mL, p = .279).</p><p><strong>Conclusions: </strong>Implementing a preoperative immunonutrition supplementation program in patients with advanced ovarian cancer undergoing primary cytoreductive surgery is feasible, and future studies are warranted to determine whether such a program improves patient outcomes.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101980"},"PeriodicalIF":4.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What should be the next control arm in prospective studies for locally advanced cervical cancer?","authors":"Kenro Chikazawa, Hiroyoshi Ko, Ken Imai, Tomoyuki Kuwata","doi":"10.1016/j.ijgc.2025.101981","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101981","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 8","pages":"101981"},"PeriodicalIF":4.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare intra-tumoral colonization of Fusobacterium nucleatum in endometrial cancer.","authors":"Mariana Bisarro Dos Reis, Denise Almeida Araújo Basso, Murilo Bonatelli, Gustavo Noriz Berardinelli, Gustavo Ramos Teixeira, Ricardo Dos Reis, Rui Manuel Reis","doi":"10.1016/j.ijgc.2025.101979","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101979","url":null,"abstract":"<p><p>The presence of Fusobacterium nucleatum has been associated with gynecological disorders, namely endometriosis and pregnancy complications; however, its role in endometrial cancer remains unexplored. This study aimed to assess the presence of intra-tumoral F nucleatum in endometrial carcinoma tissues and its association with patients' clinicopathological and molecular features. A total of 260 patients were included, and a droplet digital polymerase chain reaction assay was employed to detect F nucleatum in formalin-fixed paraffin-embedded tumor tissues. F nucleatum was detected in only 3 cases (1.2%), and none exhibited high bacterial levels, even within the 79 microsatellite instability-high molecular subgroup. These findings suggest that intra-tumoral F nucleatum does not play an oncogenic role in endometrial cancer.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 8","pages":"101979"},"PeriodicalIF":4.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and safety of robotic single-port surgical staging in epithelial ovarian cancer using the da Vinci SP platform: a preliminary experience.","authors":"Benito Chiofalo, Valentina Bruno, Emanuela Mancini, Ermelinda Baiocco, Andrea Giannini, Giorgio Bogani, Paolo Scollo, Enrico Vizza","doi":"10.1016/j.ijgc.2025.101977","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101977","url":null,"abstract":"<p><p>Minimally invasive surgery has transformed gynecologic procedures by reducing postoperative pain, accelerating recovery, and shortening hospital stays. The da Vinci SP system represents a significant advancement in single-port robotic surgery, offering articulated instruments and enhanced visualization. However, its role in staging epithelial ovarian cancer remains underexplored. We conducted a retrospective case series of patients who underwent surgical staging for epithelial ovarian cancer at the Regina Elena National Cancer Institute in Rome between September 2024 and March 2025 using the da Vinci SP system. Clinical, surgical, and postoperative data were collected, focusing on complication rates within 30 days. Seven patients were enrolled. No intraoperative conversions or complications were observed. The median hospital stay was 3 days, median blood loss was 10 mL, and the median lymph node yield was 7 (range; 5-19). No patients experienced Clavien-Dindo grade II or higher complications within 30 days. Single-port robotic staging using the da Vinci SP system appears to be a safe and feasible option for selected patients with early-stage ovarian cancer. Further prospective studies are needed to confirm these preliminary findings.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 8","pages":"101977"},"PeriodicalIF":4.1,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical outcomes of rectosigmoid colon resection versus rectosigmoid wall stripping for superficial rectal wall tumors at cytoreductions for advanced ovarian cancer.","authors":"Jaekyung Bae, Dong Woon Lee, Kiho You, Dong-Eun Lee, Ji Hyun Kim, Robert Armbrust, Sang-Yoon Park, Christina Fotopoulou, Myong Cheol Lim","doi":"10.1016/j.ijgc.2025.101973","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101973","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate surgical outcomes of rectosigmoid resection versus rectosigmoid wall stripping for superficial tumor involvement during cytoreductive surgery for advanced ovarian cancer.</p><p><strong>Methods: </strong>This retrospective study included patients with the International Federation of Gynecology and Obstetrics stage III to IV ovarian cancer who underwent rectosigmoid resection or rectosigmoid wall stripping during primary or interval cytoreductive surgery between January 2021 and January 2024. Inverse probability of treatment weighting was used to balance baseline characteristics. Perioperative and oncologic outcomes were compared using appropriate statistical tests, including χ², Fisher exact, Wilcoxon rank-sum, and Z-tests.</p><p><strong>Results: </strong>A total of 322 patients (rectosigmoid resection, n = 182; rectosigmoid wall stripping, n = 140) were included. A transition from rectosigmoid resection to rectosigmoid wall stripping began in mid-2022, resulting in an 83% reduction in rectosigmoid resection and a 900% increase in rectosigmoid wall stripping by late 2023. Rectosigmoid wall stripping was associated with shorter operation time (310 vs 400.8 minutes, p < .0001), lower blood loss (median, 489.4 vs 700 mL, p < .0001), fewer transfusions (31.3% vs 54.4%, p = .0002), shorter hospital stays (median, 11 vs 12 days, p = .0001), fewer thromboembolic events (6% vs 13.0%, p = .0356), and faster chemotherapy initiation (20 vs 22 days, p = .0002). Complete cytoreduction rates (72.6% vs 79.0%, p = .5152) and 6-month mortality (2.3% vs 1.7%, p = .6795) were similar. The rectosigmoid resection group showed a trend toward higher rates of bowel perforation (3.0% vs 0.8%) and fistula formation (2.0% vs 1.0%), although these differences were not statistically significant.</p><p><strong>Conclusions: </strong>For superficial and limited rectal serosal involvement, rectosigmoid wall stripping achieved macroscopic tumor clearance while reducing perioperative complications compared with rectosigmoid resection, which should be reserved for deeper or more extensive disease. Six-month follow-up showed comparable mortality rates between the 2 groups. Long-term and large-scale data are needed to ensure comparable oncologic safety.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 8","pages":"101973"},"PeriodicalIF":4.1,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond resistance: redefining the therapeutic landscape of platinum-resistant ovarian cancer.","authors":"Beatriz Devito Alencar de Oliveira, Mariana Carvalho Gouveia, Rafaela Melo Campos Borges, Renata Arakelian, Mariana Scaranti","doi":"10.1016/j.ijgc.2025.101974","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101974","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 8","pages":"101974"},"PeriodicalIF":4.1,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ESGO/INCIP Guidelines for the management of patients with gynecological cancers during pregnancy.","authors":"Frédéric Amant, François Planchamp, Paul Berveiller, Elyce Cardonick, Anne De Middelaer, Robert Fruscio, Monica Fumagalli, Anna L V Johansson, Matteo Lambertini, Charlotte L LeJeune, Christianne Lok, W Glenn McCluggage, Philip Poortmans, Jacek Sienko, Cristel S Hjortshøj, Marta Swierczynska, Antonia Carla Testa, Indra A Van Assche, Kristel Van Calsteren, Vincent Vandecaveye, Carolien Versteeg, Flora Zagouri, Ignacio Zapardiel, Michael J Halaska","doi":"10.1016/j.ijgc.2025.101975","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101975","url":null,"abstract":"<p><p>As part of its mission to improve the quality of care for women with gynecological cancers across Europe, the European Society of Gynecological Oncology (ESGO) organized 3 international consensus meetings with leading experts in the field to define protocols and to provide guidance for pregnant patients and healthcare providers on the management of gynecological cancers in pregnancy. Following the third consensus meeting, the guidelines published in 2019 were updated by incorporating new evidence on this field and covering new topics to provide comprehensive evidence-based guidelines on all relevant issues within a multidisciplinary setting. ESGO appointed 21 experts from relevant disciplines and 2 cancer survivors to serve on the international development group. Members of the International Network on Cancer, Infertility and Pregnancy involved in the 3 international consensus meetings were included. To ensure that the guidelines were evidence-based, data identified from a systematic search were reviewed and critically appraised. In the absence of robust scientific evidence, the guidelines were based on the consensus of the international development group. Prior to publication, the guidelines were reviewed by 100 independent international practitioners in cancer care delivery from Asia, Europe, Africa, and North and South Americas, and 3 patient representatives to ensure a global perspective. These ESGO/International Network on Cancer, Infertility and Pregnancy guidelines address all relevant aspects of imaging, pathology, surgery, medical oncology, obstetrics, radiation therapy, psychology, patient perspectives and pediatric follow-up in a multidisciplinary setting for patients with tubo-ovarian, cervical, and vulvar cancers during pregnancy. Treatment algorithms for each tumor type are also defined.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101975"},"PeriodicalIF":4.1,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility-sparing treatment in patients with placental trophoblastic site tumor: a systematic review.","authors":"Alexandros Fotiou, Chrysoula Margioula-Siarkou, Joanna Kacperczyk-Bartnik, Tibor A Zwimpfer, Konstantinos Dinas, Stamatios Petousis","doi":"10.1016/j.ijgc.2025.101972","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101972","url":null,"abstract":"<p><strong>Objective: </strong>Placental site trophoblastic tumor (PSTT) is a rare pathologic entity of gestational trophoblastic neoplasia. The main objective of the present manuscript is to summarize current evidence regarding the possibility of fertility-sparing management.</p><p><strong>Methods: </strong>A systematic review of the literature was conducted to evaluate the efficacy, oncological safety, and fertility-preservation outcomes in patients with PSTT undergoing fertility-sparing management. PubMed, Scopus, and Cochrane Library were searched to identify proper articles. Eligibility criteria included all prospective or retrospective cohorts reporting conservative management of PSTT. Primary outcomes were the rate of recurrence and fertility outcome. Secondary outcomes concerned the type of conservative management.</p><p><strong>Results: </strong>Overall, 16 articles were retrieved including a total of 63 patients. The mean age was 28.3 years (range; 21-37) and the mean serum beta-human chorionic gonadotropin was 17,251.9 IU/L (range; <0.1 to 430,290 IU/L). Regarding the antecedent pregnancy, 41.3% (26 cases) were full-term pregnancies, and 30.2% (19 cases) were abortions. Most cases were International Federation of Gynecology and Obstetrics stage I (73%). The overall recurrence rate of disease was 13.8% (8 of 63 patients) with these patients all treated with hysterectomy after recurrence. There were overall 23 full-term pregnancies reported, indicating a 36.5% fertility rate per patient, while 2 pregnancies are still ongoing at the time of publication.</p><p><strong>Conclusions: </strong>Fertility-sparing management of patients with PSTT is feasible and oncologically safe, with 36.5% fertility outcomes.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101972"},"PeriodicalIF":4.1,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to 'Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644].","authors":"Andreas Obermair, Val Gebski, Jeffrey Goh, Anna Kuchel, Alison Brand, Blossom Mak, Orla McNally, Eva Baxter, Thomas Jobling, Linda Mileshkin","doi":"10.1016/j.ijgc.2025.101961","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101961","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101961"},"PeriodicalIF":4.1,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}